The Supreme Court of Toxicology
This article was originally published in Start Up
GTCR is a Chicago investment firm which has been putting millions of dollars into the reference laboratory business in a contrarian bet that going forward, it would be a growth industry. Among its holdings are American Medical Laboratories, an esoteric reference lab, Associated Pathologists Laboratories, a reference lab in Nevada, and Dynacare, a company that specializes in joint ventures between reference labs and hospital labs. Its properties have grown and other financial investors seem interested in the lab business these days.
You may also be interested in...
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.
While cancer experts are almost giddy with enthusiasm about rapid advances in cancer immunotherapy—in a field not known for euphoria--they are equally pessimistic about market access hurdles as impediments to improved patient care and are seeking manageable approaches to assessing value.